MRI Study Reveals Brain Differences in Patients with Migraine, Offering Hope for Better Diagnostics and Treatment
Posted on April 18 2024,
A recent study published in the journal Neurology has found interesting observations on the brain structure of people with migraine. The study compared MRI scans of 296 migraine patients to 155 healthy controls, analyzing cortical surface area, thickness, and volume.
The researchers found that migraine patients, especially those with chronic migraine, had reduced cortical surface area in the left anterior insula, a region involved in pain processing. They also discovered increased surface area in the right caudal anterior cingulate cortex (ACC) in chronic migraine, which correlated with monthly headache frequency. Furthermore, migraine without aura was associated with greater right caudal ACC surface area compared to controls.
No significant differences in cortical thickness or volume were found between migraine and control groups.
The study's findings have important implications for people with migraine. The distinct brain signatures observed in different migraine subtypes suggest that personalized diagnostics and therapies may be possible in the future.
The association between medication overuse/adaptation headache and brain structure changes also highlights the need for effective preventive treatments.
Finally, this is also further evidence that migraine is not “just in your head” as some therapy people we recently talked about like to claim. It is not fear-based, but real, anatomical, and functional changes occurring in the nervous system, including the brain.
Wed, Jan 14, 26
New Emergency Department Migraine Treatment Guidelines
The American Headache Society (AHS) has released its 2025 guideline update for the acute treatment of migraine in adults presenting to the emergency department. This update, published in Headache in...
Read MoreSun, Jan 04, 26
Long-Term Safety of Anti-CGRP Monoclonal Antibodies
A comprehensive meta-analysis of over 4,300 patients reveals that erenumab, galcanezumab, fremanezumab, and eptinezumab maintain good tolerability beyond 12 months. Only 3% of patients stopped treatment due to adverse events,...
Read MoreThu, Jan 01, 26
Alternate Nostril Breathing Protocol for Migraine
Alternate nostril breathing is a simple yogic technique that's showing real promise for migraine prevention. Unlike acute treatments, this practice builds nervous system resilience over time - making attacks less...
Read More
